These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 8969323)

  • 1. Industry responsibility in interactive computer modeling.
    Mauskopf J
    Med Care; 1996 Dec; 34(12 Suppl):DS165-72. PubMed ID: 8969323
    [No Abstract]   [Full Text] [Related]  

  • 2. Current efforts in standards development. United States.
    Power EJ
    Med Care; 1996 Dec; 34(12 Suppl):DS200-3; discussion DS204-7. PubMed ID: 8969327
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacoeconomics: determining the value of drug therapy.
    Peterson C
    Healthplan; 1998; 39(3):44-50. PubMed ID: 10181751
    [No Abstract]   [Full Text] [Related]  

  • 4. The real world calls. Evolving operationalization of standards by users.
    Med Care; 1996 Dec; 34(12 Suppl):DS173-5. PubMed ID: 8999204
    [No Abstract]   [Full Text] [Related]  

  • 5. [Economic evaluation of drugs. Effectiveness in diabetes therapy].
    Schöffski O
    Dtsch Med Wochenschr; 2008 Aug; 133 Suppl 4():S106-9; discussion S124-6. PubMed ID: 18686218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Personalized medications.
    Koo V
    CMAJ; 2001 Nov; 165(11):1467-8. PubMed ID: 11762567
    [No Abstract]   [Full Text] [Related]  

  • 7. Proposed drug-drug cost effectiveness methodology.
    Gagnon JP; Osterhaus JT
    Ann Pharmacother; 2006 Mar; 40(3):524-8. PubMed ID: 16507612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The economics of drug discovery and the ultimate valuation of pharmacotherapies in the marketplace.
    Sollano JA; Kirsch JM; Bala MV; Chambers MG; Harpole LH
    Clin Pharmacol Ther; 2008 Aug; 84(2):263-6. PubMed ID: 18547999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug therapy: safety, effectiveness, and economics.
    Brandys J
    Przegl Lek; 2001; 58(4):226-8. PubMed ID: 11450340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficiency-based pharmacotherapy: the new paradigm for the 21st century in medicine.
    Soto J
    Eur J Clin Pharmacol; 2000 Nov; 56(8):525-7. PubMed ID: 11151740
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmaceutical research: cost savings through innovation.
    Cohen KR; Levy RA
    AAPPO J; 1993 Oct; 3(5):28-36. PubMed ID: 10146463
    [No Abstract]   [Full Text] [Related]  

  • 12. Accumulating evidence for the case of differential discounting.
    Postma MJ; Parouty M; Westra TA
    Expert Rev Clin Pharmacol; 2013 Jan; 6(1):1-3. PubMed ID: 23272787
    [No Abstract]   [Full Text] [Related]  

  • 13. [Use of pharmacoeconomics analyses to health protection].
    Drozd M
    Wiad Lek; 2002; 55 Suppl 1():76-9. PubMed ID: 15002222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cost-related approach for evaluating drug development programs.
    Yan EC; Chen L
    Stat Med; 2004 Sep; 23(18):2863-73. PubMed ID: 15344191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacoeconomics: historical perspective.
    Bootman JL; McGhan WF; Townsend RJ
    Ann Pharmacother; 2006 Mar; 40(3):518-9. PubMed ID: 16478813
    [No Abstract]   [Full Text] [Related]  

  • 16. [Agreement between guidelines for pharmaco-economic research and never-before-published health-economics evaluations].
    Postma MJ; Kwik JJ; Rutten WJ; de Jong-van den Berg LT; Brouwers JR
    Ned Tijdschr Geneeskd; 2002 Jun; 146(23):1082-7. PubMed ID: 12085558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis: obstacles to standardisation and its use in regulating pharmaceuticals.
    Luce BR
    Pharmacoeconomics; 1993 Jan; 3(1):1-9. PubMed ID: 10146982
    [No Abstract]   [Full Text] [Related]  

  • 18. Cost-cutting ideas: prescription drugs.
    Fish JL
    J Health Care Benefits; 1993; 3(1):10-3. PubMed ID: 10130342
    [No Abstract]   [Full Text] [Related]  

  • 19. [Discount for only one drug of the same group leads to impaired health care quality].
    Bergström R
    Lakartidningen; 2006 Feb 8-14; 103(6):387-8; discussion 388. PubMed ID: 16536044
    [No Abstract]   [Full Text] [Related]  

  • 20. Modeling for health care and other policy decisions: uses, roles, and validity.
    Johnson FR; Paul JE
    Value Health; 2002; 5(1):62-3; author reply 61-2. PubMed ID: 11873387
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.